Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECP and Mogamulizumab in Erythrodermic CTCL
NCT04930653Phase 2Recruiting
- Sponsor
- City of Hope
- Start
- Oct 2022
- Primary completion
- Jun 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of mogamulizumab in cutaneous T-cell lymphoma (CTCL), sponsored by City of Hope. Started Oct 2022; status: recruiting.
02
Drugs
mogamulizumab
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT04930653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04930653.